JAK抑制剂与斑秃患者抑郁风险降低相关
基于TriNetX国际数据库的回顾性队列研究,纳入2011至2024年诊断的斑秃患者,倾向评分匹配后每组1838例。JAK抑制剂治疗与重度抑郁障碍风险降低(aHR 0.42,95%CI 0.22-0.82,p=0.009)及抗抑郁药处方减少(aHR 0.46,95%CI 0.32-0.67,p<0.001)显著相关。
要点
- JAK抑制剂治疗与斑秃患者重度抑郁障碍发生风险降低相关。
- JAK抑制剂组新开抗抑郁药处方风险亦显著降低。
- 年轻、白人及学术医疗中心患者中关联更强。
核心结论
- 斑秃患者使用JAK抑制剂与重度抑郁障碍发病率及抗抑郁药使用显著降低相关。
研究设计与样本
- 回顾性队列研究,利用TriNetX国际医疗数据库纳入2011年1月1日至2024年6月30日诊断的斑秃患者。
- 按诊断后6个月内是否使用JAK抑制剂分组,经倾向评分匹配后每组1838例进行分析。
主要发现
- JAK抑制剂组重度抑郁障碍风险显著降低(aHR 0.42,95%CI 0.22-0.82,p=0.009)。
- JAK抑制剂组抗抑郁药处方风险显著降低(aHR 0.46,95%CI 0.32-0.67,p<0.001)。
- 上述关联在1年、3年、5年和10年期间保持一致。
- 亚组分析显示在18-29岁、白人种族及学术医疗中心治疗的患者中关联更强。
临床怎么用
- 选择斑秃治疗方案时可综合考虑JAK抑制剂对心理健康的潜在获益。
- 早期使用JAK抑制剂可能同时改善斑秃患者的躯体与心理结局。
局限性
- 为观察性研究,不能确立因果关系。
- 需随机对照试验证实上述发现并探索JAK抑制剂的长期安全性与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alopecia areata (AA) is associated with a significant psychological burden, particularly an increased risk of major depressive disorder (MDD). Janus kinase (JAK) inhibitors are emerging as an effective treatment for AA, yet their impact on MDD risk remains unclear. Understanding this association could inform treatment decisions and improve patient outcomes. OBJECTIVES: This study aimed to determine if treatment with JAK inhibitors is associated with a reduced incidence of MDD in AA patients compared to those receiving other treatments or no treatment. METHODS: This study utilized the TriNetX international healthcare database, including patients diagnosed with AA between 1 January 2011 and 30 June 2024. Patients were categorized into two groups based on JAK inhibitor use within 6 months after AA diagnosis. Propensity score matching ensured balanced groups across observed covariates. The primary outcome was MDD diagnosis between 6 months and 5 years after AA diagnosis. Secondary outcomes included new antidepressant prescriptions. RESULTS: After matching, 1838 patients in each group (conventional treatments with or without JAK inhibitors) were analysed. Treatment with JAK inhibitors was significantly associated with a lower risk of MDD [aHR: 0.42, 95% confidence interval (CI): 0.22-0.82, p = 0.009] and antidepressant prescriptions (aHR: 0.46, 95% CI: 0.32-0.67, p < 0.001). These findings were consistent across 1-year, 3-year, 5-year and 10-year periods. Subgroup analyses revealed stronger associations in younger patients (18-29 years), those of White ethnicity, and those treated at academic medical centres. CONCLUSIONS: This study shows that JAK inhibitor treatment in AA patients is associated with a significantly lower incidence of MDD and reduced antidepressant use. These findings suggest a potential role for JAK inhibitor in improving mental health in AA. Randomized controlled trials are warranted to confirm these findings and explore the long-term safety and benefits of JAK inhibitors. UNLABELLED: WHAT IS THE DISEASE?: Alopecia areata (AA) is an autoimmune condition that causes patchy hair loss on the scalp and other parts of the body. It affects people of all ages and often leads to emotional distress, low self‐esteem and depression. LOCATION OF THE STUDY: This study utilized data from TriNetX, an international healthcare database encompassing hospitals across multiple countries, including the United States and nations within the European Union. AIM OF THE STUDY: We aimed to find out whether patients with AA who were treated with a newer group of medications called Janus kinase (JAK) inhibitors had a lower risk of developing major depressive disorder (MDD), compared to those who received other treatments or no treatment. METHODOLOGY: We analysed health records from over 3600 patients with AA, dividing them into two groups: those who used JAK inhibitors within 6 months of diagnosis and those who did not. We matched the two groups to ensure a fair comparison and followed them for up to 10 years to track depression diagnoses and antidepressant use. KEY FINDINGS: Patients who received JAK inhibitors had a significantly lower risk of developing depression and were less likely to be prescribed antidepressants. This benefit was consistent across different age groups, time periods and clinical settings. CONCLUSIONS AND PRACTICAL IMPLICATIONS: JAK inhibitors may offer mental health benefits for patients with AA, in addition to promoting hair regrowth. These results support considering mental well‐being when selecting treatment options and suggest that early use of JAK inhibitors may help improve both physical and psychological outcomes in AA.
引用
- Ho CY, Wu HL, Dai YX, et al. Association of Janus kinase inhibitors with reduced depression in alopecia areata. J Eur Acad Dermatol Venereol. 2025. PMID: 41239919. doi:10.1111/jdv.70184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。